by Dr. Ed Weber | Sep 4, 2025 | PCa Commentary
Background: In 1970 the antigen, PSA, was found in semen and prostate tissue. In 1980, it entered clinical service to guide biopsies for suspected cancer and monitor prostate cancer treatment. Before this, prostate cancer was diagnosed, often at a late stage, by...
by Dr. Ed Weber | Sep 4, 2025 | PCa Commentary
Background: Neuroendocrine cells are normal constituents of the prostate. They perform a regulatory role influencing growth and differentiation. Spread throughout the body, they receive signals from the nervous system to secrete hormones that govern other systems. ...
by Dr. Ed Weber | Sep 4, 2025 | PCa Commentary
Prologue: The first issue of the PCa Commentary, October 1, 2002, featured the pivotal importance of the androgen receptor in all phases of prostate cancer … and the androgen receptor’s significance continues today. Background: Research in 1941 by the physiologist...
by Dr. Ed Weber | Sep 4, 2025 | PCa Commentary
The PSMAfore protocol was FDA approved on March 28, 2025, moving the option of using [177Lu]-PSMA-617 front-forward in early progressive metastatic castration-resistant prostate cancer (mCRPC). Currently, metastatic castration-resistant PC is treated with...
by Dr. Ed Weber | Jun 23, 2025 | PCa Commentary
Brief Review of Findings in the Original Langley Abstract Presented at Eur Soc Med Oncol, Sept. 2024: The PATCH Trial established that transdermal estradiol (tE2) patches were equally effective as Lupron in achieving metastasis-free and overall survival in newly...
